Conclusion of MOU with Oxford LATAM research group, Brazil

Remedy & Company Corporation (Located in Chiyoda-ku, Tokyo, Japan; Group CEO: Masakuni Ukita, hereinafter referred to as “We”), have concluded a Memorandum of Understanding (MOU) with the Brazil-based Oxford LATAM research group, regarding the promotion of and network building for clinical trials in South America.

Oxford LATAM research group’s parent organization is the renowned Oxford University of the United Kingdom. While Japan faced many difficulties to rapidly conduct clinical trials to develop drug treatment and vaccine when the COVID-19 pandemic struck, as this research group has already established a network for trial conduction within Brazil and other regions of South America to carry out trials rapidly, when COVID-19 pandemic hit them, they were able to react quickly and handled it successfully.

Conclusion of an MOH with such a top-level international research group in the infectious disease field can undoubtedly help us expand the network of our platform for global research and development to South America. This can thereby create more opportunities more clinical trials on drug treatment, vaccine and diagnostic reagent originated from Japan in the South American region.

Furthermore, with respective MOUs with Universidad Peruana Cayetano Heredia and Oxford LATAM research group in place, we have decided to expand the capacity for enrollment of our “Platform for global development of infectious disease” to 500,000 patients.

As a front-runner in the research area of infectious disease in Asia, we understand the difficulty in enrolling sufficient subjects for these trials. Since some infectious diseases such as Neglected Tropical Disease (NTD) tuberculosis and malaria are endemic, clinical trials on drug treatment and vaccine for these diseases are best studied locally. We believe by forming networks these, we can enrich our portfolio and provide our clients with services of better value and wider range of options.